Clinical and translational radiation oncology · 2026
Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tilki Burak, Guler Ozan Cem, Demirhan Birhan, Hurmuz Pervin, Elmalı Ayşenur, Kumru Tolunay, Ozyigit Gokhan, Yavuz Melek, Onal Cem
Аннотация
PURPOSE: To evaluate clinical outcomes, patterns of failure, local control (LC), and time to next systemic therapy (TTNT) in patients with bone-only oligometastatic bladder cancer treated with stereotactic body radiotherapy (SBRT).
MATERIALS AND METHODS: We retrospectively analyzed 26 patients with 41 bone metastases treated with SBRT between 2012 and 2020 across four institutions. All patients had ≤3 bone metastases and received metastasis-directed therapy to all lesions. Overall survival (OS), progression-free survival (PFS), TTNT, and LC were estimated using the Kaplan-Meier method.
RESULTS: After a median follow-up of 97.8 months, median OS was 8.9 months, with 1- and 2-year OS rates of 38.5% and 22.4%, respectively. Median PFS was 5.8 months, with 1- and 2-year PFS rates of 29.4% and 25.2%, respectively. Median TTNT was 4.4 months, and only 19.8% of patients remained free from systemic therapy at 1 year. Disease progression occurred in 46.2% of patients and was predominantly distant metastasis. In contrast, LC was excellent, with 1- and 2-year rates of 94.7% and 88.0%, respectively. No grade ≥ 3 toxicities were observed.
CONCLUSION: SBRT achieved excellent LC with minimal toxicity. However, systemic progression remained common. These findings suggest that prospective studies are needed to determine the role of SBRT within multimodal treatment strategies for bone-only oligometastatic bladder cancer.
MATERIALS AND METHODS: We retrospectively analyzed 26 patients with 41 bone metastases treated with SBRT between 2012 and 2020 across four institutions. All patients had ≤3 bone metastases and received metastasis-directed therapy to all lesions. Overall survival (OS), progression-free survival (PFS), TTNT, and LC were estimated using the Kaplan-Meier method.
RESULTS: After a median follow-up of 97.8 months, median OS was 8.9 months, with 1- and 2-year OS rates of 38.5% and 22.4%, respectively. Median PFS was 5.8 months, with 1- and 2-year PFS rates of 29.4% and 25.2%, respectively. Median TTNT was 4.4 months, and only 19.8% of patients remained free from systemic therapy at 1 year. Disease progression occurred in 46.2% of patients and was predominantly distant metastasis. In contrast, LC was excellent, with 1- and 2-year rates of 94.7% and 88.0%, respectively. No grade ≥ 3 toxicities were observed.
CONCLUSION: SBRT achieved excellent LC with minimal toxicity. However, systemic progression remained common. These findings suggest that prospective studies are needed to determine the role of SBRT within multimodal treatment strategies for bone-only oligometastatic bladder cancer.